ideasIdea
One definitive ketogenic diet trial in glioblastoma, then stop
Patients with brain tumours are sold ketogenic diets on the strength of mouse data and small feasibility studies. A single adequately powered trial with dietitian support would either prove it or let clinicians say clearly that it does not work.
Fifteen years of feasibility studies have shown ketogenic diets are tolerable for a few months in glioblastoma and have not shown efficacy. Because the diet is marketed directly to patients and is a common reason for conflict with treating teams, the cost of not knowing is high. No company will fund a diet trial; a philanthropic or cooperative-group trial with adherence biomarkers (blood ketones), a pre-registered stopping rule and a commitment to publish either way is the appropriate instrument.
Hypothesis
A supervised ketogenic diet maintained for six months alongside standard chemoradiation and temozolomide does not improve overall survival in newly diagnosed glioblastoma compared with a standard healthy diet (null hypothesis to be tested with power to detect a 3-month median difference).
Rationale
The Warburg rationale is plausible but tumours adapt to use ketones and lactate; steroids undermine ketosis; ERGO2 was null but brief. A definitive answer protects patients from an intervention with real costs (weight loss, quality of life, expense) if it fails, and mobilises adoption if it works.
What would test it
Randomised phase 2/3 (about 300 patients) in newly diagnosed IDH-wildtype glioblastoma, stratified by MGMT status and steroid use, with dietitian-delivered ketogenic diet vs Mediterranean-style diet, ketone-verified adherence, OS primary endpoint, quality of life and body composition secondary, and pre-registered publication regardless of result.
Maturity
early clinical
Who has to act
philanthropy
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Misinformation and unproven therapies · Patients are sold unproven treatments and frightened away from proven ones.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.